How to Assess Alcohol Craving in Euthymic Dual-Diagnosis Patients
How should clinicians assess alcohol craving severity and related biologic risk in euthymic patients with alcohol use disorder and a comorbid mood disorder?
Patients with alcohol use disorder and a comorbid mood disorder can remain vulnerable to craving even when they are not in an acute mood episode. This workflow applies to adults with AUD plus major depressive disorder or bipolar disorder and helps clinicians combine mood-state confirmation, craving assessment, alcohol-use severity, and biomarkers to identify patients who may need closer monitoring.
-
Confirm the dual diagnosis and eligibility profile
Establish that the patient has AUD comorbid with major depressive disorder or bipolar disorder type I or II. In the study, diagnoses were confirmed with the Mini-International Neuropsychiatric Interview Plus, and patients with additional substance use disorders other than nicotine or with severe psychiatric, neurologic, or relevant medical conditions were excluded.
-
Verify that the patient is euthymic at assessment
Assess current mood state before interpreting craving findings. The study defined euthymia as a Montgomery-Asberg Depression Rating Scale score of 4 or lower and a Young Mania Rating Scale score below 12, to exclude residual depressive symptoms and subthreshold manic symptoms.
-
Measure current alcohol craving with a visual analog scale
Use the Visual Analog Scale as a self-report measure of craving intensity at the time of evaluation. This gives a point-in-time estimate of craving severity that can be compared across patients and interpreted alongside alcohol-use severity and laboratory markers.
-
Assess hazardous and harmful alcohol use with AUDIT
Administer the Alcohol Use Disorder Identification Test to quantify alcohol-related severity. In both the MDD and BD groups, higher VAS craving scores were positively correlated with higher AUDIT scores, with P<.001 in each group.
-
Obtain CDT and plasma homocysteine levels
Collect venous blood samples during the clinical evaluation to measure carbohydrate-deficient transferrin and plasma homocysteine. In both diagnostic groups, higher craving severity was positively correlated with higher CDT percentage and higher homocysteine concentration, supporting their use as biologic correlates of a more severe dual-diagnosis profile.
-
Interpret findings in light of mood disorder subtype
Do not treat euthymic MDD and euthymic BD as interchangeable when evaluating craving burden. In this sample, patients with AUD comorbid with MDD had significantly higher VAS scores, higher AUDIT scores, and greater CDT percentage than patients with AUD comorbid with BD, despite euthymia.
-
Use convergent clinical and biologic elevation to flag higher-risk patients
When elevated craving co-occurs with higher AUDIT, CDT, and homocysteine, consider the patient to have a more severe profile that may warrant closer monitoring and more intensive, integrated treatment strategies. The article frames these combined elevations as markers of increased neurobiological vulnerability rather than as stand-alone diagnostic tests.
Clinical Considerations
- The study was cross-sectional, so these assessments identify associations and cannot establish causality or predict the temporal direction of relapse risk.
- The sample was small and the diagnostic groups were unequal in size, which limits robustness of between-group comparisons.
- The bipolar group included both BD I and BD II, and the study could not determine whether craving patterns differ by bipolar subtype.
- The findings come from a single outpatient addiction treatment center with few female participants, which may limit generalizability.
Bottom Line
In euthymic patients with AUD and a mood disorder, assess craving with VAS and pair it with AUDIT, CDT, and homocysteine, while recognizing that craving burden was higher in comorbid MDD than in comorbid BD.